India Pharma - IPM Growth Broadly Normalised In June: Prabhudas Lilladher
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
Indian pharmaceutical market growth broadly normalised in the month of June 2021 after strong sales growth in April and May 2021, led by second wave of Covid-19 and lower base benefits.
The key reasons for normalised growth are:
declining number of active Covid-19 cases post its peak in May-21 during the second wave,
IPM supply chain getting largely streamlined in June-20, hence base become normalised versus April-May-20,
high demand for anti-infective/acute-therapy products on a lower base and
high contributions in incremental growth of IPM from Covid-19 related preventive medicines maintained.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.